HyQvia

HyQvia is used in adults and children with immunodeficiency syndromes. These are patients whose blood does not contain enough antibodies (proteins that help the body to fight infections and other diseases), also known as immunoglobulins. HyQvia is used to treat: - primary immunodeficiency syndromes (PID, when patients are born with an inability to produce enough antibodies); - secondary immunodeficiency syndrome (SID, when patients have developed inability to produce enough antibodies as a result of another condition or treatment). HyQvia is used in patients who have serious or recurrent infections for which current treatments do not work and who have low blood levels of immunoglobulin G (IgG) or who are not able to produce sufficient levels of IgG in response to infections; - chronic inflammatory demyelinating polyneuropathy (CIDP) after the patient is stabilised on intravenous immunoglobulins. In this condition, the immune system (the body’s defence system) works abnormally and destroys the protective covering over the nerves causing nerve problems such as weakness and numbness. HyQvia contains the active substance human normal immunoglobulin. The product also contains recombinant human hyaluronidase, which is an enzyme used to help the active substance to disperse under the skin and improve its absorption into the body. HyQvia contains the active substance human normal immunoglobulin. The product also contains recombinant human hyaluronidase, which is an enzyme used to help the active substance to disperse under the skin and improve its absorption into the body.